Saturday, June 27, 2026

Cardiology Malpractice: Recurring Failure Patterns and the Lessons They Teach

Risk Management & Practice

Cardiology Malpractice: Recurring Failure Patterns and the Lessons They Teach

Closed-claims data and litigated cases point to three preventable failure modes — and a clear playbook for closing them.

Physician EducationPractice & Risk Management10 min read

Most cardiologists will face a malpractice allegation at some point in their career.

The costliest and most common allegation, by a wide margin, is a failure to diagnose.

A 2026 closed-claims analysis from The Doctors Company reviewed 321 cardiology malpractice cases closed between 2010 and 2025 and found that diagnosis-related and medical-treatment allegations each accounted for roughly a third of all claims.

Reading those cases side by side with a recently published American College of Cardiology case review reveals the same three failure points again and again.

None of them require a procedural complication or a rare disease — most involve an ordinary patient whose ordinary symptoms were filed under the wrong diagnosis for too long.

What Closed Cardiology Claims Allege

Diagnosis-related 36% Medical treatment 36% Medication-related 13% Surgical treatment 7% Source: closed-claims dataset, 321 cases, 2010–2025
Diagnosis-related and medical-treatment allegations each appear in roughly a third of closed cardiology claims; categories are not mutually exclusive, since a single case often carries more than one allegation.

The Anatomy of a Closed Claim

Only a minority of filed claims ever result in a payment to the patient.

In the 321-case dataset, just 31% closed with an indemnity payment, and the average paid claim cost roughly $394,000 against a mean defense expense of about $79,000 regardless of outcome.

What separated the paid claims from the dismissed ones was rarely a single dramatic error.

It was almost always a contributing factor embedded somewhere in the workup, the procedure, or the chart.

Table 1 — Contributing factors in paid cardiology claims
Contributing factorShare of claimsMean payment
Clinical judgment69.2%$398,000
Communication breakdown41.4%$384,000
Behavior-related factors28.4%$429,000
Documentation gaps22.4%$387,000
Technical skill deficits13.4%$404,000

Data: The Doctors Company closed-claims review, reported via Becker's ASC, 2026.

Notice that behavior-related factors carry the highest average payment of any category, even though they appear less often than clinical-judgment lapses.

Juries and reviewers tend to punish dismissiveness toward a patient's concerns more harshly than a defensible clinical miss.

Pattern One — Anchoring on a Cardiac Masquerader

The most instructive case in the ACC's review involved a patient with hypertension, a smoking history, and chronic obstructive pulmonary disease who presented to a primary care office with neck, chest, and abdominal pain.

A same-day chest radiograph showed vascular congestion, yet the visit ended with a diagnosis of cervicalgia and the patient was sent home.

Two days later the same patient arrived at the emergency department with an ECG showing Q waves and was ultimately found to have an NSTEMI, but cardiac catheterization did not occur until roughly twelve hours after admission.

Expert reviewers agreed that the standard of care — consistent with the ACC/AHA/SCAI revascularization guideline — called for catheterization within two to four hours given the patient's ongoing symptoms and evidence of evolving heart failure, and the cardiologist named in the suit could not be defended on that point.

Timeline of a Litigated NSTEMI Delay

Day 1 PCP visit — "cervicalgia" Day 3 ED arrival — Q waves, cardiology consult +2–4 hrs Guideline-recommended catheterization window +12 hrs Catheterization actually performed Gap unsupported by any defense expert 100% proximal LAD occlusion found at catheterization; LVEF 30–35% post-PCI. Patient died one month later of heart and respiratory failure.
Case detail adapted and paraphrased from a closed-claims case review published by the American College of Cardiology; reflects a single litigated case, not a universal timeline.

Closed-claims data from Maryland courts, compiled by a personal-injury firm that tracks cardiologist malpractice verdicts and settlements, shows the same anchoring pattern across very different presentations.

One settlement involved a patient with a known bicuspid aortic valve whose endocarditis was initially read as sinusitis, which allowed the infection to progress to sepsis and stroke before cardiology was consulted.

Another verdict involved a patient whose chest pain was attributed to non-cardiac panic attacks without further cardiac testing, and who collapsed from a fatal heart attack weeks later.

A third settlement followed a patient recovering from bypass surgery whose new symptoms were attributed to pneumonia and medication side effects rather than to an evolving aortic dissection, a recognized complication of the index operation.

In each case, the index symptom had a plausible benign explanation — and the chart shows no documented consideration of the cardiac alternative until it was too late.

The ACC review adds an important caveat worth repeating in any practice: women remain underdiagnosed and undertreated in acute coronary syndrome, and smoking, diabetes, depression, and anxiety can present as stronger or more confounding risk signals in women than in men.

Pattern Two — Procedural Vigilance Doesn't End When the Sheath Comes Out

A second cluster of claims involves patients who did fine during the index procedure and then deteriorated afterward.

One closed claim described a post-catheterization hematoma that progressed to uncontrolled internal bleeding, with allegations centered on a delay in ordering blood products and surgical intervention rather than on the index procedure itself.

The Doctors Company's risk-management guidance flags a related and very specific blind spot: postablation symptoms such as fever, fatigue, nausea, or vomiting need prompt in-person or telehealth evaluation, not a phone call or a portal message.

The same guidance calls out a cognitive trap clinicians should recognize in themselves — attributing fever and vomiting to "the flu" during flu season in a medically complex, recently instrumented patient is a textbook example of anchoring bias.

The lesson generalizes well beyond ablation: any new symptom in the days after a catheterization, device implant, or structural procedure deserves the same threshold for in-person evaluation that the index complaint did.

Pattern Three — The Result That Never Closed the Loop

Communication breakdowns are present in roughly four of every ten paid cardiology claims, and several closed cases show exactly why.

In more than one closed claim, an abnormal exercise stress test or imaging finding was generated, reported, and then never acted upon — sometimes because the result was relayed as reassuring when it was not, and sometimes because no one tracked that the recommended follow-up testing had not occurred.

None of these failures required a missed diagnosis at the moment of testing; they required a system that let a flagged result sit unresolved.

A documented, closed-loop process for abnormal results is one of the few risk-reduction strategies that is entirely within a practice's control, independent of how busy or complex any single day becomes.

Table 2 — Failure pattern, vulnerability, and the fix
Failure patternWhere it hidesRisk-reduction strategy
Anchoring on a benign diagnosis Atypical chest, neck, or abdominal pain attributed to musculoskeletal, infectious, or anxiety-related causes Document the cardiac differential explicitly, even when ruling it out, especially in women and atypical presenters
Post-procedural symptom drift Fever, bleeding, or hypotension after catheterization or ablation managed remotely Default to in-person or telehealth evaluation for any new post-procedural symptom — never phone or message alone
Unclosed result loop Abnormal stress test, imaging, or lab result generated but not tracked to action Build a hard-stop tracking system so every abnormal result is acknowledged and documented before the chart closes

Inside the Claim: How a Malpractice Case Actually Unfolds

Knowing the failure patterns matters less if the litigation process itself feels like a black box.

A practical overview of the medical malpractice litigation process from Cardiology Magazine walks through exactly how a claim moves from a first letter to a final resolution, and the sequence is worth internalizing before it is ever needed.

The Path of a Malpractice Claim

1 Early indicators Records request or notice of claim 2 Statute of limitations Filing window opens, typically 1–3 years 3 Record integrity Chart is frozen — never amended 4 Discovery Interrogatories, depositions, experts 5 Resolution Dismissal, settlement, or trial Where most claims actually end up 80–90% of defensible claims are dismissed with no settlement at all. 96.9% of claims that do pay out are settled — not decided by a jury. The full process commonly runs 2–5 years from notice to resolution.
Process and figures paraphrased from Cardiology Magazine's overview of the medical malpractice litigation process; individual jurisdictions and case facts vary.

1 & 2 — The First Signals and the Clock

The earliest hint of a possible suit is often nothing more than a routine-looking records request from a patient or an attorney, and not every request signals litigation.

A more definite signal is a formal notice of claim, and a number of states require either a pre-suit notice of intent or a review by a screening panel before a case can proceed to court.

The clock on all of this is the statute of limitations, generally one to three years from the date of the alleged injury, though the exact window varies by state and can differ for minors or patients who lack legal capacity.

3 — Protecting the Record

Once a clinician has any reason to suspect a claim, the medical record must be treated as frozen exactly as it stands.

Defense attorneys routinely retain forensic document experts, and for electronic records, an EHR metadata audit can reconstruct every keystroke, deletion, and timestamp after the fact.

A record shown to have been altered after the fact does more than weaken a defense — it can expose a clinician to punitive damages and a separate licensing board inquiry.

4 — Discovery, Depositions, and Experts

Most of the substantive work in a malpractice case happens during pre-trial discovery, where both sides exchange written interrogatories and take oral depositions.

A deposition is frequently the single most consequential event before trial, and the best-prepared physicians answer only the question asked, resist the urge to fill silence with extra detail, and say "I don't recall" rather than guess.

Expert witnesses retained by each side ultimately do the real work of defining what the standard of care required and whether it was met.

5 — How Claims Actually End

The headline figures bear repeating because they run counter to most physicians' intuition about their own risk: roughly 80% to 90% of defensible claims are dismissed with no payment at all, and of the claims that do result in payment, about 97% are resolved by settlement rather than a jury verdict.

The entire process, start to finish, commonly takes two to five years, with long stretches of inactivity between bursts of legal work.

None of this changes the clinical lessons above, but it does mean that a well-documented, well-defended case is statistically very likely to end in dismissal — which is one more reason the chart, written in real time, is worth protecting.

Case Vignette

A 56-year-old with hypertension, type 2 diabetes, and a 30-pack-year smoking history presents to an urgent care clinic with two days of intermittent neck tightness, mild nausea, and fatigue.

Vital signs are normal, a screening ECG is not performed, and the visit closes with a diagnosis of musculoskeletal strain and a recommendation to follow up if symptoms worsen.

The patient returns 36 hours later in the emergency department with frank substernal pressure, and an ECG now shows new T-wave inversions with a mildly elevated troponin.

Applying the patterns above, the most defensible version of the first visit would have documented the cardiac risk factors, obtained a same-visit ECG given the multiple risk factors present, and given explicit, written return precautions rather than a general "follow up if worse" instruction.

The clinical outcome may not always change, but the documentation of a reasoned cardiac differential — and a low threshold for objective testing in a high-risk patient — is precisely what separates a defensible miss from a successful claim.

Bottom Line

The cardiology claims most likely to result in payment rarely involve rare diseases or technical failures; they involve atypical ACS presentations anchored to a benign diagnosis, post-procedural symptoms managed remotely instead of in person, and abnormal results that were generated but never closed out.

All three are addressable with documentation habits and triage thresholds that cost nothing to implement and have nothing to do with diagnostic difficulty.

This article is intended for physician education and reflects publicly reported litigation outcomes and aggregate closed-claims data; it is not legal advice, does not establish a standard of care for any individual patient, and case outcomes vary by jurisdiction and specific facts. Clinicians with questions about an active or potential claim should consult their professional liability carrier and defense counsel directly.

Friday, June 26, 2026

New York Valves 2026: The Late-Breaking Data Cardiologists Should Know

New York Valves 2026: The Late-Breaking Data Cardiologists Should Know

A high-yield digest of the trial updates, registry data, and guideline signals presented at structural heart's flagship June meeting.

More than 3,000 interventional cardiologists, surgeons, and imagers convened at the Jacob K. Javits Convention Center for New York Valves 2026, the structural heart community's flagship June meeting.

Across three days, the program delivered roughly 30 late-breaking presentations spanning aortic, mitral, and tricuspid disease, alongside a dedicated left atrial appendage closure (LAAC) summit and six FDA town halls.

For clinicians who could not attend in person, five storylines stand out for their bearing on everyday valve referral and follow-up decisions.

3,000+Attendees
30Late-breaking presentations
4+2LB clinical science / innovation sessions
1.5 daysLAAC summit
20Live-case sessions
6FDA town halls

Figure 1. New York Valves 2026 by the numbers.

Asymptomatic Severe AS: Rethinking "Watch and Wait"

The asymptomatic severe aortic stenosis (AS) debate anchored the opening session, built around an updated 5-year analysis of the EARLY TAVR trial.

Early transcatheter aortic valve replacement (TAVR) continued to outperform clinical surveillance for the composite of death, stroke, or unplanned cardiovascular hospitalization, reinforcing the trial's original findings.

A parallel session reviewed 7-year valve durability data from PARTNER 3, which showed comparable clinical outcomes and hemodynamic performance between TAVR and surgical replacement in low-risk patients.

Taken together, both data sets support a lower threshold for intervention in anatomically suitable, low-risk patients rather than indefinite serial echocardiographic surveillance.

The 2025 ESC/EACTS valvular heart disease guidelines have already moved in this direction, now endorsing intervention in asymptomatic patients with severe high-gradient AS and preserved ejection fraction when procedural risk is low.

Tricuspid Regurgitation: Durability Signals Emerge

Tricuspid disease received its own late-breaking session, headlined by 2-year outcomes from TRISCEND II.

Transcatheter tricuspid valve replacement (TTVR) sustained reduction in tricuspid regurgitation and symptom benefit through 2 years compared with medical therapy alone.

Investigators also flagged an early signal toward a mortality advantage, a finding that, if it holds up, would mark a meaningful shift for a disease long managed expectantly.

Companion talks addressed device thrombosis after TTVR and outcomes of edge-to-edge repair in patients who had already failed a first repair attempt, underscoring that tricuspid intervention is maturing past first-generation questions.

Mitral Disease: Filling the Anatomic Gaps

The single late-breaking mitral session centered on patients who fall outside standard device indications.

One-year registry data on transcatheter mitral valve replacement in mitral annular calcification suggested a feasible option for a population historically excluded from both surgery and edge-to-edge repair.

Additional presentations compared real-world outcomes between two leading mitral edge-to-edge repair systems and examined repeat repair in patients whose first procedure had failed.

Collectively, these analyses chip away at the remaining "no-option" mitral phenotypes that heart teams routinely encounter.

Pure Aortic Regurgitation: A Pacemaker Trade-off

Native aortic regurgitation (AR) remains underserved by conventional TAVR platforms, which are engineered around calcified anatomy.

A dedicated-device trial, ALIGN-AR, has shown high technical success and elimination of significant residual AR using a valve built specifically for non-calcified annuli.

The trade-off has been a new permanent pacemaker rate near one in four patients, and a late-breaking analysis at the meeting examined predictors of that pacing need.

Until a dedicated device gains broader approval, off-label TAVR in pure AR should remain a heart-team decision made with this pacing risk clearly in view.

Screening and Innovation: Finding What the Eye Misses

A late-breaking innovation session highlighted AI-enabled ECG screening that flags structural heart disease from a standard 12-lead tracing.

In one published case, the algorithm identified previously unrecognized severe AS in an asymptomatic patient who went on to TAVR, illustrating how automated screening can shorten the path from incidental finding to definitive treatment.

This kind of tool complements the Target: Aortic Stenosis initiative, a national quality program built to close the persistent gap between echocardiographic AS diagnosis and timely referral.

Closing the diagnosis-to-treatment gap, rather than developing yet another device, may be where the next incremental survival benefit in AS actually comes from.

Day 1 — Wed

TAVI durability (PARTNER 3) and tricuspid late-breakers; asymptomatic AS debate opens the Heart Team Arena; LAAC Summit begins.

Day 2 — Thu

Mitral late-breakers (MAC, repeat M-TEER); AI-ECG innovation session; postapproval TMVR landscape.

Day 3 — Fri

2025 ESC aortic guideline review; AS registries (PROGRESS, DETECT AS II); ALIGN-AR pacemaker analysis.

Figure 2. How the late-breaking science was distributed across the three meeting days.

Table 1. Late-Breaking Data Snapshot — New York Valves 2026
Trial / RegistryValve DomainFollow-upHeadline Finding
EARLY TAVRAortic — asymptomatic severe AS5 yearsEarly TAVR sustained lower death/stroke/unplanned CV hospitalization vs. surveillance
PARTNER 3Aortic — low-risk symptomatic AS7 yearsTAVR and SAVR comparable on death/stroke/rehospitalization and valve durability
TRISCEND IITricuspid regurgitation2 yearsSustained TR reduction and symptom benefit; early mortality signal
ALIGN-ARNative aortic regurgitation30 days–1 yearEliminated significant residual AR; ~1-in-4 new pacemaker rate
TMVR-MAC registryMitral annular calcification1 yearFeasible option in anatomy excluded from surgery/edge-to-edge repair
AI-ECG screeningCross-valvularCase-levelFlagged unrecognized severe AS, prompting TAVR referral
Table 2. What Changed: 2025 ESC/EACTS Practice Signals
Clinical ScenarioPrior Practice Norm2025 Guideline Direction
Asymptomatic severe high-gradient AS, low riskSerial echo surveillanceEarlier intervention reasonable if procedural risk is low
Tricuspid (trileaflet) ASTAVI favored ≥75 yearsAge threshold lowered to ≥70 years
Atrial secondary mitral regurgitationNo dedicated recommendationNew Class IIa surgery / IIb transcatheter guidance
Pure native AR, high surgical riskOff-label TAVR onlyDedicated-device data supportive; pacemaker risk a key counseling point
Undiagnosed structural heart diseaseSymptom- or murmur-triggered echoAI-ECG screening adds an asymptomatic detection pathway
Case in Point

A 74-year-old man with no cardiac symptoms undergoes a routine preoperative ECG before elective hip surgery, and an AI-enabled ECG algorithm flags the tracing as suggestive of structural heart disease.

Echocardiography reveals severe, high-gradient AS with preserved ejection fraction, and a negative treadmill test confirms his asymptomatic status.

Under older surveillance-only norms, he would likely have been scheduled for a repeat echocardiogram in 12 months and sent on to surgery.

Citing the 2025 ESC/EACTS guidance and the updated EARLY TAVR follow-up data, the heart team instead pursues earlier TAVR evaluation given his low procedural risk and favorable anatomy, illustrating how this year's data and screening tools can change a default decision pathway.

Bottom Line
  • Updated EARLY TAVR follow-up and the 2025 ESC/EACTS guidelines both now favor earlier intervention over indefinite surveillance in low-risk, anatomically suitable asymptomatic severe AS.
  • TTVR is maturing past symptom relief alone, with 2-year TRISCEND II data hinting at a mortality benefit that warrants longer follow-up.
  • Pure native AR is treatable with a dedicated transcatheter device, but patients should be counseled on a roughly 1-in-4 new pacemaker rate.
  • AI-enabled ECG screening is an emerging, low-cost lever for catching unrecognized structural heart disease before symptoms force the issue.

References

  1. What's Going to Be Hot at New York Valves 2026 — TCTMD
  2. New York Valves 2026 To Unveil Late-Breaking Research in Structural Heart Disease — Cardiovascular Research Foundation
  3. New York Valves 2026 — Conference Overview
  4. PARTNER 3: TAVR vs. Surgery in Low-Risk Patients at 7 Years — American College of Cardiology
  5. EARLY TAVR: 5-Year Data Still Support TAVI Over Surveillance in Asymptomatic AS — TCTMD
  6. Hints of a Mortality Benefit With TTVR at 2 Years: TRISCEND II — TCTMD
  7. TAVR With JenaValve for Symptomatic Aortic Regurgitation in High Surgical Risk Patients — American College of Cardiology
  8. 2025 ESC/EACTS Guidelines for the Management of Valvular Heart Disease — European Society of Cardiology
  9. Target: Aortic Stenosis — American Heart Association
  10. Cardiologists Develop New AI Screening Tool for Structural Heart Disease — Cardiovascular Business

This article is intended for physician education and summarizes publicly presented and published data. It is not a substitute for individualized clinical judgment, current society guidelines, or multidisciplinary Heart Team decision-making for any specific patient.

One Tracer, All Amyloid: The Evuzamitide and REVEAL Story

Cardiac Imaging · Nuclear Cardiology

One Tracer, All Amyloid: The Evuzamitide and REVEAL Story

A pan-amyloid PET radiotracer just cleared its pivotal Phase III hurdle — here's what it could mean for a diagnosis that still takes years.

The Diagnostic Gap

Despite growing physician awareness, cardiac amyloidosis remains substantially underdiagnosed.

Current estimates place the worldwide disease burden at roughly 400,000 patients, and that figure is widely considered an undercount.

A diagnostic journey of two to four years from first symptom to confirmed diagnosis remains common, often crossing several specialists and imaging studies before an answer emerges.

Part of the problem is structural, since today's noninvasive toolkit was never built to answer one question for every patient.

Bone-avid scintigraphy using technetium-99m pyrophosphate, DPD, or HMDP is highly specific for ATTR cardiac amyloidosis at Perugini grade 2 or 3, but its sensitivity for ATTR runs only around 70%, it cannot reliably identify AL amyloid, and a coexisting monoclonal protein forces a confirmatory biopsy regardless of how the scan looks.

Beta-amyloid PET tracers repurposed from Alzheimer's imaging, such as florbetapir and Pittsburgh compound B, can detect both AL and ATTR disease, but neither was designed around a structural feature shared by every amyloid subtype.

None of these established tools were built to quantify amyloid burden or track its change with treatment, a gap that matters more each year as ATTR stabilizers, gene silencers, and AL-directed therapies reshape how response is measured.

One Peptide, Every Amyloid Type

Evuzamitide, radiolabeled with iodine-124, is built around a synthetic 45-amino-acid peptide called p5+14 rather than around any single amyloid precursor protein.

The peptide folds into an alpha helix that aligns twelve positively charged lysine residues along one face, allowing electrostatic binding to the densely negative surface that essentially all amyloid fibrils share.

That same electrostatic logic extends to the heavily sulfated heparan sulfate proteoglycans that accompany amyloid deposits in tissue, a biochemical signature shown to be distinct from the lower-sulfated glycans found in healthy organs.

Because the binding target is structural rather than protein-specific, evuzamitide uptake has been documented across AL kappa, AL lambda, wild-type and variant ATTR, leukocyte chemotactic factor-2, gelsolin, apolipoprotein-A1, lysozyme, and serum amyloid A amyloidosis in human imaging studies.

In practical terms, the same single injection and scan can answer the detection question no matter which amyloid protein turns out to be the culprit.

What the Early Data Showed

The first-in-human Phase 1/2 study enrolled 50 patients with systemic amyloidosis alongside two asymptomatic ATTR variant carriers and five healthy controls.

Cardiac uptake was visually present in nearly every patient with known cardiac involvement and absent in every healthy control, translating into an overall sensitivity of 93.6% for amyloid detection.

A head-to-head pilot comparison against florbetapir found comparable diagnostic performance in AL cardiac amyloidosis but greater myocardial uptake with evuzamitide in ATTR disease, raising the possibility of an edge in the more common amyloid subtype.

Quantitative uptake also correlated with established markers of disease severity, including interventricular septal thickness, left ventricular mass index, global longitudinal strain, and extracellular volume on echocardiography and cardiac MRI.

Whole-body imaging additionally captured extracardiac amyloid in the kidney, liver, spleen, and soft tissue, which matters most in systemic AL disease, where multi-organ burden drives prognosis.

A published case report used serial evuzamitide PET to track falling cardiac amyloid burden in a patient with AL amyloidosis responding to plasma-cell-directed immunotherapy, hinting at a treatment-monitoring role that no currently available cardiac amyloid tracer fully offers.

The tracer's whole-body effective dose, about 9 mSv per standard 1 mCi injection, falls in the same range as routine PET myocardial perfusion imaging, and no drug-related serious adverse events or anti-peptide antibodies were observed.

REVEAL Brings It to Phase III

The pivotal REVEAL study moved evuzamitide from mechanistic promise to a prespecified, adequately powered diagnostic trial.

REVEAL enrolled 170 adults with suspected cardiac amyloidosis across 19 United States centers in a multicenter, open-label, single-arm design.

Each participant received one intravenous dose of evuzamitide followed by cardiac and partial-body PET/CT imaging three to five hours later, with scans read visually by cardiac PET physicians blinded to clinical data.

The reference standard was an independent, blinded adjudication of standard-of-care diagnosis using each center's routine clinical workup, completed within 60 days of the scan.

The trial's prespecified hypothesis was that visual evuzamitide PET would exceed 65% sensitivity and 55% specificity for cardiac amyloidosis against that standard-of-care reference, with secondary analyses planned separately for ATTR and AL subtypes.

In May 2026, the sponsor announced that REVEAL met both primary endpoints — sensitivity and specificity for visual diagnosis of cardiac amyloidosis — though specific point estimates have not yet been released pending presentation at a scientific congress.

Evuzamitide carries FDA Breakthrough Therapy Designation for cardiac amyloidosis imaging and Orphan Drug status for both AL and ATTR amyloidosis in the United States and European Union, and the sponsor has indicated plans to discuss regulatory submission with health authorities following REVEAL.

It remains an investigational compound that has not been approved by any regulatory authority for any indication, and the topline data summarized above have not yet undergone peer review.

Table 1. Cardiac amyloidosis imaging tools at a glance
ModalityAL detectionATTR detectionQuantifies burdenMonoclonal protein issueWhole-body imaging
⁹⁹ᵐTc-PYP / DPD / HMDP scintigraphyNot validatedYes — ~70% sensitivity at Perugini 2–3Semi-quantitative grade onlyBiopsy required if presentNo
¹⁸F-florbetapir / ¹¹C-PiB (β-amyloid PET)YesYes — generally lower uptake than ATTR-specific tracersYes (SUV / retention index)Not a confounderYes
¹²⁴I-evuzamitide (pan-amyloid PET)YesYes — comparable to or greater than florbetapirYesNot a confounderYes, whole-body
Table 2. Evuzamitide development snapshot
MilestoneStatus
Orphan Drug status (AL & ATTR, US/EU)Granted
FDA Breakthrough Therapy DesignationGranted, August 2024
Phase 1/2 first-in-human study93.6% sensitivity in 50 amyloidosis patients
Phase III REVEAL study170 adults, 19 US centers — completed
REVEAL topline resultsPrimary endpoints met, May 2026
Full REVEAL datasetPending presentation at scientific congress
Regulatory submissionDiscussions planned with FDA and other health authorities
Companion SPECT tracer (⁹⁹ᵐTc-p5+14)Same peptide platform, investigational

Case Vignette

A 78-year-old man presents with progressive exertional dyspnea and bilateral lower-extremity edema, and his echocardiogram shows increased left ventricular wall thickness with preserved ejection fraction.

Serum free light chain testing reveals a small monoclonal kappa elevation, and bone scintigraphy shows grade 2 myocardial tracer uptake.

Under current diagnostic rules, the presence of a monoclonal protein invalidates scintigraphy as a stand-alone test, so guideline-directed workup still requires an endomyocardial or fat-pad biopsy with mass spectrometry typing before a treatment pathway — ATTR stabilizer versus AL-directed chemotherapy — can be chosen with confidence.

A pan-amyloid PET tracer is designed for exactly this scenario, since the same scan that confirms amyloid deposition is present, regardless of fibril type, could in principle pair with light-chain typing to support a faster diagnosis while also revealing whether amyloid extends beyond the heart.

Where It Could Fit: A Proposed Algorithm

No society has written evuzamitide into a guideline yet, so what follows is an illustrative algorithm built from the current ESC-style nonbiopsy pathway, not an endorsed clinical pathway.

The logic rests on one mechanistic limit worth stating up front: a pan-amyloid signal confirms that amyloid is present, but it does not by itself prove which protein is depositing it, so light-chain and genetic testing stay in the loop.

The proposed insertion point is at the imaging step itself, either replacing bone scintigraphy as the initial confirmatory scan or, more conservatively, serving as a problem-solver wherever scintigraphy and serology disagree.

Established step today Proposed evuzamitide step, if approved Decision point / biopsy trigger
Step 1 · Today
Clinical suspicion of cardiac amyloidosis — HFpEF, unexplained LV wall thickening, ECG–echo voltage discordance, low-flow low-gradient severe aortic stenosis, bilateral carpal tunnel syndrome, or a family history of ATTR.
Step 2 · Today
Order together: echo/cardiac MRI characterization and serum/urine immunofixation with free light chains, to screen for a monoclonal protein before any imaging result is interpreted.
Step 3 · If approved
Pan-amyloid PET (evuzamitide) performed as the confirmatory cardiac scan, in place of or alongside bone scintigraphy, with whole-body acquisition to flag extracardiac uptake in the same sitting.

PET negative

Cardiac amyloidosis effectively excluded given the tracer's high sensitivity in early studies — pursue alternative causes of hypertrophy or heart failure, and biopsy is generally avoided.

PET positive, no monoclonal protein

ATTR cardiac amyloidosis is highly likely without further tissue confirmation — proceed directly to TTR genotyping to separate wild-type from variant disease, then start ATTR-directed therapy.

PET positive, monoclonal protein present

Subtype remains indeterminate — could be ATTR-CA with incidental MGUS, or true AL-CA — so endomyocardial or fat-pad biopsy with mass spectrometry typing is still required before committing to a treatment pathway.

PET equivocal or discordant with prior scintigraphy

Correlate with CMR late gadolinium enhancement and extracellular volume, or refer to a specialized amyloidosis center; biopsy if the picture stays unresolved.
Step 4 · If approved & validated
Serial evuzamitide PET after diagnosis and treatment initiation, to quantify change in myocardial amyloid burden alongside NT-proBNP, troponin, and free light chains — a monitoring function no current cardiac amyloid tracer offers.

Two deployment models are realistic, and the sponsor's own language leans toward the second: evuzamitide could become the front-line confirmatory scan for every patient with suspected cardiac amyloidosis, or it could enter more conservatively as a second-tier tool reserved for the indeterminate scintigraphy-plus-serology combinations that drive biopsy referrals today.

Which model wins out will depend on the subtype-specific sensitivity and specificity from the full REVEAL dataset, the wording of any eventual FDA label, and whether cardiology and nuclear medicine societies choose to revise their nonbiopsy diagnostic algorithms once that data is public.

Why It Matters for Practice

If the full REVEAL dataset confirms the topline signal, the clinical case for a single, subtype-agnostic test becomes straightforward to articulate to patients and referring colleagues alike.

A tracer that performs across AL and ATTR disease could shorten the diagnostic odyssey for patients whose presentation does not fit cleanly into either established pathway, particularly those with a coincidental monoclonal protein or an atypical TTR variant.

The same quantitative, whole-body readout that detects disease could eventually support staging extracardiac involvement and tracking treatment response over time, functions that current bone-avid and beta-amyloid tracers were not built to deliver.

None of this changes today's guideline-based workflow, and scintigraphy plus monoclonal protein screening remains the standard first step until evuzamitide, if approved, earns a defined place in that algorithm.

Bottom Line

  • Evuzamitide is a pan-amyloid PET radiotracer designed to detect AL, ATTR, and rarer amyloid subtypes with a single test, addressing a gap no existing cardiac amyloid imaging tool fully closes.
  • Phase 1/2 data showed 93.6% sensitivity for amyloid detection, and the pivotal Phase III REVEAL trial has now met its prespecified primary endpoints for sensitivity and specificity against standard-of-care diagnosis.
  • It remains investigational, the full REVEAL dataset is still unpublished, and it is not yet available for clinical use while the sponsor pursues regulatory submission.
  • If approved, its quantitative, whole-body, subtype-agnostic profile could reshape how clinicians detect, differentiate, and monitor cardiac amyloidosis in everyday practice.

For physician education only. Evuzamitide is investigational and is not approved by the FDA, EMA, or any other regulatory authority for any indication. Topline trial results discussed here have not undergone peer review and are subject to change upon full data publication.

EARLY TAVR at 5 Years: Durable Support for Early Intervention in Asymptomatic Severe Aortic Stenosis

 New landmark-analysis data presented at NY Valves 2026 show that the early-TAVI advantage seen in the original EARLY TAVR trial persists out to five years, with the death-and-stroke benefit concentrated almost entirely after the two-year mark.

For decades, the default approach to severe aortic stenosis without symptoms has been to wait.

Guidelines have long recommended routine surveillance every six to twelve months until a patient develops dyspnea, angina, syncope, or another qualifying symptom that triggers valve replacement.

That paradigm has been steadily eroding since 2019, and the newest data presented this week push it further still.

What the New Data Show

At a median follow-up approaching five years, patients randomized to early transcatheter aortic valve implantation had a significantly lower rate of the composite of death, stroke, or heart failure hospitalization than those managed with clinical surveillance (15.2% vs 24.2%; HR 0.58, 95% CI 0.43–0.78).

Critically, a landmark analysis starting at the two-year mark found that this advantage was not simply carried forward from early hospitalizations driven by elective valve replacement in the surveillance arm.

Beyond two years, early intervention still carried a lower risk of the composite endpoint (HR 0.65, 95% CI 0.43–0.98), and the death-or-stroke benefit specifically emerged almost entirely in this later window (HR 0.61, 95% CI 0.40–0.94).

In other words, the two strategies tracked together for death and stroke through year two, then diverged.

FIGURE 1 · ILLUSTRATIVE EVENT-RATE TRAJECTORY0 yr12345 yr0%25%2-yr landmarkSurveillanceEarly TAVI
Schematic rendering, not the original Kaplan-Meier plot, illustrating the reported pattern: the two strategies track closely for death and stroke through year two, then separate as crossover and natural-history events accumulate in the surveillance arm.
TABLE 1 · EARLY TAVR — 5-YEAR OUTCOMES
EndpointEarly TAVISurveillanceEffect Estimate
Composite: death, stroke, or HF hospitalization15.2%24.2%HR 0.58 (0.43–0.78)
Composite, landmark from year 2HR 0.65 (0.43–0.98)
All-cause death10.3%12.3%HR 0.84 (0.57–1.24)
Stroke4.8%7.6%HR 0.63 (0.37–1.07)
Death or stroke13.4%17.5%95% CI for HR, 0.53–1.04
Death or stroke, landmark from year 2HR 0.61 (0.40–0.94)
Heart failure hospitalization3.5%10.3%HR 0.32 (0.18–0.57)
HF hospitalization, landmark from year 2HR 0.61 (0.26–1.42)

Why the Curves Separate at Two Years

By the two-year mark, roughly three in four patients assigned to surveillance had already crossed over to valve replacement, mostly because they developed symptoms.

That crossover explains why the early heart-failure-hospitalization benefit narrows after year two: once nearly everyone has a valve, the groups converge on that particular outcome.

What does not converge is death and stroke, and one proposed explanation is that the waiting period itself, rather than just the underlying valve disease, accounts for a meaningful share of strokes and deaths in patients left in a hemodynamically stressed, untreated state.

Postulated late mechanisms in the surveillance arm include valve underexpansion at the time of eventual implantation, embolic events related to a heavily calcified untreated valve, new-onset atrial fibrillation, and acute decompensation syndromes that develop once compensatory reserve is exhausted.

Those mechanisms remain hypothesis-generating rather than proven, and a full accounting is expected when the complete 5-year dataset is reported in the next one to two years.

Severe AS Definition and the Decision Pathway

The trial's inclusion criteria are a useful refresher on how "truly asymptomatic" severe AS was operationalized: an aortic valve area of 1.0 cm² or less (or an area index of 0.6 cm²/m² or less) with a mean transaortic gradient of at least 40 mmHg or a peak jet velocity of at least 4.0 m/s, confirmed asymptomatic by a negative treadmill stress test or, in a minority, detailed history alone.

FIGURE 2 · FROM DIAGNOSIS TO DECISIONConfirm severe ASAVA ≤1.0 cm² · Vmax ≥4 m/snegative stress testHeart-team reviewTF-suitable anatomylow surgical risk, ≥65 yrEarly TAVISurveillance~75% cross to AVRby 2 years
Simplified decision pathway derived from the EARLY TAVR protocol; real-world surveillance intervals and crossover thresholds should follow current institutional and society guidance.

Regulatory and Practice Context

These findings build on a trajectory that began with the original trial publication and culminated in the FDA's 2025 approval of the balloon-expandable transcatheter platform for asymptomatic severe AS, the first such approval in this population.

That approval converted a research question into a bedside option, and it means clinicians can now have a genuine shared-decision conversation about timing rather than defaulting to watchful waiting by guideline inertia alone.

A parallel late-breaking trial in 2024, summarized alongside EARLY TAVR in ACC's meeting coverage, tested whether myocardial fibrosis on MRI could identify asymptomatic patients most likely to benefit from early intervention and found no significant advantage for that imaging-guided strategy, which keeps the EARLY TAVR anatomic and hemodynamic criteria as the more actionable framework for now.

TABLE 2 · RANDOMIZED EVIDENCE FOR EARLY INTERVENTION IN ASYMPTOMATIC SEVERE AS
TrialInterventionN / Follow-upPrimary Result
EARLY TAVRTransfemoral TAVI901 pts · 5 yr15.2% vs 24.2%, HR 0.58
AVATARSurgical AVR157 pts · 32 mo15.2% vs 34.7%, HR 0.46
RECOVERYSurgical AVR145 pts · 6 yrCV death 1% vs 15%

AVR, aortic valve replacement; CV, cardiovascular; HR, hazard ratio; pts, patients.

ILLUSTRATIVE CASE

A 74-year-old man is referred after a routine echocardiogram shows an aortic valve area of 0.9 cm², a mean gradient of 46 mmHg, and a peak velocity of 4.3 m/s, with preserved ejection fraction and no reported dyspnea, angina, or syncope.

A treadmill stress test is negative for symptoms or an abnormal blood-pressure response, confirming truly asymptomatic severe AS, and CT angiography shows favorable transfemoral access with no other contraindication to intervention.

Rather than defaulting to surveillance imaging in six months, the heart team uses the 5-year EARLY TAVR data to frame a shared decision: proceed now with a roughly 9-point absolute reduction in 5-year composite events, or accept surveillance with a high probability of eventual crossover and a residual stroke signal that does not fully resolve even after a valve is later placed.

The patient elects early TAVI and is scheduled within the month.

Practical Takeaways

  • The death-and-stroke benefit of early intervention is concentrated after year two, which argues against framing early TAVI as merely "pulling forward" an inevitable procedure.
  • Nearly three-quarters of surveillance patients in the trial crossed over to AVR by two years, so a true watch-and-wait strategy in this population is, in practice, a watch-and-convert strategy for most patients.
  • Trial eligibility was anchored to age 65 or older, low surgical risk, transfemoral-suitable anatomy, and rigorously confirmed asymptomatic status, so extrapolation to younger, higher-risk, or borderline-symptomatic patients should remain cautious.
  • The 5-year dataset is still incomplete, with complete follow-up available in roughly 80% of the TAVI arm and 72% of the surveillance arm, and a fuller report is expected within the next one to two years.
BOTTOM LINE

Five-year follow-up reinforces that early TAVI outperforms guideline-recommended surveillance in carefully selected patients with truly asymptomatic severe aortic stenosis, with the death-and-stroke advantage emerging specifically after the two-year mark rather than being an artifact of early crossover.

For patients who meet EARLY TAVR's anatomic, hemodynamic, and risk criteria, this supports offering a heart-team discussion about prompt intervention rather than reflexively scheduling another six-month echocardiogram.